Venture Megadeals Surge as Biotech Outpaces AI in Late-Stage Funding
Despite a high rate of down rounds, U.S. startups see a boom in $100 million-plus funding rounds in 2024. Surprisingly, biotech and healthcare lead the mega-deal categories, surpassing artificial intelligence.
Venture capitalists insist the funding bear market ends as late-stage megadeals surge in 2024. Crunchbase tracks nearly 240 U.S. funding rounds of $100 million or more this year, easily surpassing the 210 mega-rounds recorded throughout all of last year. This boom occurs even though nearly 39% of late-stage deals remain down rounds, proving that top-tier companies still attract massive capital infusions.
Surprisingly, artificial intelligence does not top the list of categories for these enormous funding rounds. Biotech and healthcare startups account for 87 mega-deals, while AI companies secure only 26 deals to claim second place. Some of these large rounds naturally overlap as founders combine artificial intelligence with drug discovery, creating crossover investments that appeal to both traditional tech investors and specialized life science funds.
Notable examples include Xaira Therapeutics, which launches with a $1 billion round backed by biotech specialists and Silicon Valley heavyweights like Sequoia Capital. Other healthcare deals, such as the $120 million Series A for Superluminal Medicines, focus on specific drug creation without relying on AI hype. These investments highlight a clear investor appetite for tangible biotech innovations that attract major players like Nvidia's venture arm and Insight Partners.